ClinicalTrials.gg
Status unknownNCT00004981Updated Jun 24, 2005

Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)

A Phase 3 interventional study of Abacavir sulfate, Lamivudine and Zidovudine and Lamivudine/Zidovudine in HIV Infections, sponsored by Glaxo Wellcome. Status unknown at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Glaxo Wellcome (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2001), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
230
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.

Enrollment
44th of 126
230 · median 154
Phase 3
50 of 132
2 open now
Registered
42nd of 132
by date
Lead sponsor
12 of 132
Glaxo Wellcome

Among the 132 studies testing lamivudine in HIV Infections, this one is the 44th largest by enrollment of the 126 interventional ones that give a count, is one of 50 in phase 3, and was the 42nd registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing lamivudine in HIV Infections, or all of them as a file.
02

Study summary

The purpose of this study is to look at the safety and effectiveness of a pill called Trizivir that is a combination of three anti-HIV drugs (zidovudine, lamivudine, and abacavir). Zidovudine and lamivudine are often given combined in one pill (Combivir). In this study, Trizivir will be compared to Combivir plus abacavir.

Read the detailed description

Patients are randomized to receive either the triple combination tablet (Trizivir) or to receive Combivir plus abacavir as a separate tablet. Patients take their study medications for 24 weeks.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Drug Therapy, Combination
  • Zidovudine
  • Drug Administration Schedule
  • Lamivudine
  • RNA, Viral
  • Reverse Transcriptase Inhibitors
  • Anti-HIV Agents
  • Viral Load
  • Combivir
  • abacavir
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients may be eligible for this study if they:

  • Are at least 18 years old.
  • Are -positive.
  • Are currently receiving one of the following anti-HIV drug combinations: Combivir plus abacavir, Combivir plus abacavir plus a protease inhibitor, or Combivir plus abacavir plus a non-nucleoside reverse transcriptase inhibitor (NNRTI). Patients must have been taking this drug combination for at least the past 16 weeks. This also must be the first anti-HIV drug combination the patient has received.
  • Have a viral load (level of HIV in the blood) less than or equal to 400 copies/ml.
  • Have greater than 200 cells/mm3.
  • Agree to use effective methods of .

Exclusion criteria

Exclusion Criteria

Patients will not be eligible for this study if they:

  • Have been diagnosed with AIDS.
  • Have a gastrointestinal disorder that makes it difficult for patients to absorb food or to take medications by mouth.
  • Have hepatitis.
  • Have a serious medical condition, such as diabetes, congestive heart failure, or other heart disease.
  • Are allergic to any of the study drugs.
  • Abuse alcohol or drugs.
  • Will not be available for the entire 24-week study period.
  • Are pregnant or breast-feeding.
  • Have taken or will need to take certain medications, including radiation therapy, chemotherapy, drugs that affect the immune system (such as interleukin), an vaccine, foscarnet, and hydroxyurea.
  • Are enrolled in another experimental drug study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Enrollment
230 participants

Interventions

06

Study locations

25 sites
  • AIDS Healthcare Foundation
    Los Angeles, California 900276069, United States
  • Tower Infectious Disease Med Ctr
    Los Angeles, California 90048, United States
  • Robert Scott MD
    Oakland, California 94609, United States
  • St Lukes Medical Group
    San Diego, California 92101, United States
  • Georgetown Univ Med Ctr
    Washington, District of Columbia 20007, United States
  • Whitman Walker Clinic
    Washington, District of Columbia 20009, United States
  • Univ of Miami School of Medicine
    Miami, Florida 33136, United States
  • Specialty Med Care Ctrs of South Florida Inc
    Miami, Florida 33142, United States
  • Saint Josephs Comprehensive Research Institute
    Tampa, Florida 33607, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30308, United States
  • Rush Presbyterian - Saint Luke's Med Ctr
    Chicago, Illinois 60612, United States
  • New England Med Ctr
    Boston, Massachusetts 02111, United States
  • Research Med Ctr
    Kansas City, Missouri 64111, United States
  • Addiction Research and Treatment Corp
    Brooklyn, New York 11201, United States
  • Saint Vincent's Hosp and Med Ctr
    New York, New York 10011, United States
  • St Luke Roosevelt Hosp
    New York, New York 10011, United States
  • Lehigh Valley Hosp
    Allentown, Pennsylvania 18105, United States
  • Hahnemann Univ Hosp
    Philadelphia, Pennsylvania 191021192, United States
  • Anderson Clinical Research
    Pittsburgh, Pennsylvania 15213, United States
  • Burnside Clinic
    Columbia, South Carolina 29206, United States
  • Univ of Tennessee
    Memphis, Tennessee 38163, United States
  • Nashville Health Management Foundation / Vanderbilt Univ
    Nashville, Tennessee 37203, United States
  • Nicholas Bellos
    Dallas, Texas 75246, United States
  • Univ of Texas Med Branch
    Galveston, Texas 77555, United States
  • Therapeutic Concepts
    Houston, Texas 77004, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00004981
Lead sponsor
Glaxo Wellcome
First posted
Aug 31, 2001
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2001. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lamivudine · Zidovudine · Abacavir

Start the discussion